company background image
6578

DaBomb Protein TPEX:6578 Stock Report

Last Price

NT$16.00

Market Cap

NT$632.2m

7D

-3.6%

1Y

-9.1%

Updated

24 Sep, 2022

Data

Company Financials
6578 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

6578 Stock Overview

DaBomb Protein Corp. produces and supplies plant peptides in Asia.

DaBomb Protein Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DaBomb Protein
Historical stock prices
Current Share PriceNT$16.00
52 Week HighNT$28.85
52 Week LowNT$16.00
Beta0.49
1 Month Change-10.36%
3 Month Change-11.11%
1 Year Change-9.09%
3 Year Change-31.25%
5 Year Change-35.29%
Change since IPO-49.60%

Recent News & Updates

Shareholder Returns

6578TW Personal ProductsTW Market
7D-3.6%-3.0%-3.1%
1Y-9.1%-1.0%-17.6%

Return vs Industry: 6578 underperformed the TW Personal Products industry which returned -1% over the past year.

Return vs Market: 6578 exceeded the TW Market which returned -17.6% over the past year.

Price Volatility

Is 6578's price volatile compared to industry and market?
6578 volatility
6578 Average Weekly Movement4.6%
Personal Products Industry Average Movement5.6%
Market Average Movement5.0%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 6578 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6578's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aYu Fen Liuhttps://www.dabombprotein.com

DaBomb Protein Corp. produces and supplies plant peptides in Asia. It offers pet healthcare products under the Lactotides name; plant probiotic peptides under the Agrigood name; bio stimulants under the Dabomb Ti name; antibiotics-free feed under the DaBomb-p (Aqua) and DaBomb-p (Livestock) names; and immune-synbiotic boosters under the DaBomb Live name. The company was founded in 2001 and is based in Tainan City, Taiwan.

DaBomb Protein Fundamentals Summary

How do DaBomb Protein's earnings and revenue compare to its market cap?
6578 fundamental statistics
Market CapNT$632.25m
Earnings (TTM)-NT$52.35m
Revenue (TTM)NT$465.42m

1.4x

P/S Ratio

-12.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6578 income statement (TTM)
RevenueNT$465.42m
Cost of RevenueNT$448.95m
Gross ProfitNT$16.47m
Other ExpensesNT$68.83m
Earnings-NT$52.35m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.32
Gross Margin3.54%
Net Profit Margin-11.25%
Debt/Equity Ratio69.9%

How did 6578 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 6578 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6578?

Other financial metrics that can be useful for relative valuation.

6578 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-20.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6578's PS Ratio compare to its peers?

6578 PS Ratio vs Peers
The above table shows the PS ratio for 6578 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.1x
4136 Thai Ho Group
0.3xn/aNT$275.8m
4109 Jia Jie Biomedical
4.8xn/aNT$1.4b
6242 Li Kang Biomedical
2.2xn/aNT$1.1b
4732 NatureWise Biotech & Medicals
5.1xn/aNT$1.5b
6578 DaBomb Protein
1.4xn/aNT$632.2m

Price-To-Sales vs Peers: 6578 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (3.1x).


Price to Earnings Ratio vs Industry

How does 6578's PE Ratio compare vs other companies in the TW Personal Products Industry?

Price-To-Sales vs Industry: 6578 is good value based on its Price-To-Sales Ratio (1.4x) compared to the TW Personal Products industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is 6578's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6578 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6578's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6578 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6578's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6578's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is DaBomb Protein forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.8%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DaBomb Protein has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of 6578’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has DaBomb Protein performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-67.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6578 is currently unprofitable.

Growing Profit Margin: 6578 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6578 is unprofitable, and losses have increased over the past 5 years at a rate of 67.8% per year.

Accelerating Growth: Unable to compare 6578's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6578 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-11.6%).


Return on Equity

High ROE: 6578 has a negative Return on Equity (-7.01%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is DaBomb Protein's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 6578's short term assets (NT$363.8M) exceed its short term liabilities (NT$251.6M).

Long Term Liabilities: 6578's short term assets (NT$363.8M) exceed its long term liabilities (NT$311.4M).


Debt to Equity History and Analysis

Debt Level: 6578's net debt to equity ratio (37%) is considered satisfactory.

Reducing Debt: 6578's debt to equity ratio has increased from 7.4% to 69.9% over the past 5 years.

Debt Coverage: 6578's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 6578's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is DaBomb Protein current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6578's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6578's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6578's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6578's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 6578 is not paying a notable dividend for the TW market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6578 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yu Fen Liu

no data

Tenure

Ms. Yu Fen Liu serves as Chairman and General Manager of DaBomb Protein Corp. Ms. Liu served as the Chairman of Board of Directors in DaBomb Protein Company Limited. Ms. Liu holds EMBA Degree from National...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.

Company Information

DaBomb Protein Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: DaBomb Protein Corp.
  • Ticker: 6578
  • Exchange: TPEX
  • Founded: 2001
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: NT$632.248m
  • Shares outstanding: 39.52m
  • Website: https://www.dabombprotein.com

Number of Employees


Location

  • DaBomb Protein Corp.
  • No.52, Gongye 3rd Road
  • Tainan City
  • 709
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6578TPEX (Taipei Exchange)YesOrdinary SharesTWTWDJul 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.